ORAVERSE Drug Patent Profile
✉ Email this page to a colleague
When do Oraverse patents expire, and what generic alternatives are available?
Oraverse is a drug marketed by Septodont Holding and is included in one NDA.
The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oraverse
A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ORAVERSE?
- What are the global sales for ORAVERSE?
- What is Average Wholesale Price for ORAVERSE?
Summary for ORAVERSE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 110 |
Clinical Trials: | 6 |
Patent Applications: | 1,014 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ORAVERSE |
What excipients (inactive ingredients) are in ORAVERSE? | ORAVERSE excipients list |
DailyMed Link: | ORAVERSE at DailyMed |
![ORAVERSE drug patent expirations Drug patent expirations by year for ORAVERSE](/p/graph/s/t/ORAVERSE-patent-expirations.png)
![Drug Prices for ORAVERSE](/p/graph/drug-price/ORAVERSE.png)
Recent Clinical Trials for ORAVERSE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cairo University | Phase 3 |
sara nabil | Phase 3 |
Dalhousie University | Phase 4 |
Pharmacology for ORAVERSE
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |
US Patents and Regulatory Information for ORAVERSE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ORAVERSE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ORAVERSE
See the table below for patents covering ORAVERSE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Portugal | 1280531 | ⤷ Sign Up | |
Hong Kong | 1079444 | 穩定的阿爾法腎上腺素能受體拮抗藥製劑及其用途 (STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF) | ⤷ Sign Up |
Japan | 4787977 | ⤷ Sign Up | |
European Patent Office | 1762236 | Formulations d'antagonistes des récepteurs adrénergiques alpha et leurs utilisations (Formulations of alpha adrenergic receptor antagonists and their uses) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |